Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01720446 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,297
- Enrollment target
NCT01720446: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT01720446 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 3,297 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (327% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01720446, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,297 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopping criteria are met.
Primary Outcome
Percentage of subjects experiencing a first event of a major adverse cardiovascular event (MACE), defined as cardiovascular (CV) death, non-fatal myocardial infarction (MI), or non-fatal stroke.
Interventions
- DRUG placebo
- DRUG semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,297 participants |
| Start Date | 2013-02-21 |
| Est. Completion | 2016-03-15 |
| Phase | Phase 3 |
What the finished NCT01720446 record still lists
NCT01720446 is an interventional study that assigns participants to a tested intervention. Its 3,297 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (327% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01720446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01720446 about?
NCT01720446 is a clinical study titled "Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes". This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovas...
What is the current status of trial NCT01720446?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,297 participants. The study started on 2013-02-21. Estimated completion is 2016-03-15.
What interventions are being tested in trial NCT01720446?
The interventions under investigation include: placebo (DRUG), semaglutide (DRUG).
Who is sponsoring clinical trial NCT01720446?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01720446's enrollment target sits among peer trials
3,297 72nd of 2000 higher than 1,929 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07214610 · 3,300 participants · NA
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- NCT06815536 · 3,291 participants
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
- NCT06543446 · 3,290 participants · NA
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI